Linker Matters: Highly Stable & Efficient ADCs Utilizing Novel Native Antibodies & Peptide Linker Technology to Improve PK Exposure, Therapeutic Efficacy & Tolerability
Time: 2:00 pm
day: Conference Day One - Track 1 - PM
Details:
- A novel peptide linker technology for site-specific payload conjugation will be introduced that enables the generation of antibody-drug conjugates (ADCs) from native antibodies in one step
- Resulting ADCs show antibody-like PK exposure with excellent activity and tolerability
- Topoisomerase-1 inhibitor ADCs were generated showing superior efficacy vs. trastuzumab deruxtecan in several animal models, highlighting the potential of this innovative peptide linker technology in enhancing the therapeutic efficacy and tolerability of ADCs
